- Home
- CDXS vs CCCC Comparison
CDXS vs CCCC Comparison
Compare CDXS & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDXS
- CCCC
- Stock Information
- Founded
- CDXS 2002
- CCCC 2015
- Country
- CDXS United States
- CCCC United States
- Employees
- CDXS N/A
- CCCC N/A
- Industry
- CDXS Major Chemicals
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- CDXS Industrials
- CCCC Health Care
- Exchange
- CDXS Nasdaq
- CCCC Nasdaq
- Market Cap
- CDXS 230.3M
- CCCC 244.9M
- IPO Year
- CDXS 2010
- CCCC 2020
- Fundamental
- Price
- CDXS $2.11
- CCCC $1.25
- Analyst Decision
- CDXS Buy
- CCCC Buy
- Analyst Count
- CDXS 2
- CCCC 4
- Target Price
- CDXS $11.00
- CCCC $12.50
- AVG Volume (30 Days)
- CDXS 1.1M
- CCCC 1.1M
- Earning Date
- CDXS 05-01-2025
- CCCC 05-07-2025
- Dividend Yield
- CDXS N/A
- CCCC N/A
- EPS Growth
- CDXS N/A
- CCCC N/A
- EPS
- CDXS N/A
- CCCC N/A
- Revenue
- CDXS $59,345,000.00
- CCCC $35,584,000.00
- Revenue This Year
- CDXS $12.62
- CCCC N/A
- Revenue Next Year
- CDXS $22.11
- CCCC $36.31
- P/E Ratio
- CDXS N/A
- CCCC N/A
- Revenue Growth
- CDXS N/A
- CCCC 71.44
- 52 Week Low
- CDXS $1.90
- CCCC $1.09
- 52 Week High
- CDXS $6.08
- CCCC $7.66
- Technical
- Relative Strength Index (RSI)
- CDXS 35.96
- CCCC 32.58
- Support Level
- CDXS $1.91
- CCCC $1.09
- Resistance Level
- CDXS $2.47
- CCCC $1.32
- Average True Range (ATR)
- CDXS 0.21
- CCCC 0.15
- MACD
- CDXS 0.02
- CCCC 0.02
- Stochastic Oscillator
- CDXS 23.86
- CCCC 25.58
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.